Atossa Therapeutics Inc. (NASDAQ:ATOS) does about 563.52K shares in volume on a normal day but saw 206077 shares change hands in Friday trading. The company now has a market cap of 101.59M USD. Its current market price is $0.80, marking a decrease of -0.80% compared to the previous close of $0.81. The 52 week high reached by this stock is $1.62 whilst the lowest price level in 52 weeks is $0.50. The script in recent trading has seen the stock touch a high of $0.8191 and a low of $0.78.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Atossa Therapeutics Inc. (ATOS) has a 20-day trading average at $0.7962 and the current price is -50.48% off the 52-week high compared with 60.46% distance from its 52-week low. The 50-day simple moving average of the closing price is $0.7148 and its 200-day simple moving average is $0.8838. If we look at the stock’s price movements over the week, volatility stands at 8.24%, which decreases to 7.46% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 53.54 to suggest the stock is neutral.
1 analysts observing the Atossa Therapeutics Inc. (ATOS) stock have set the 12-month price targets for the company’s shares at between $6.00 and $6.00. The consensus objective for the share price is $6.00, suggesting that the stock has a potential upside of 86.67% over the period. The median price target is 86.67% away from the current levels at $6.00.
FactSet Research has provided data showing that 1 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 1 analysts have rated it as a buy and 0 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Moderate Buy the stock.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on January 26, 2018 when Maxim Group initiated the stock to “Buy” and issued a price target of $2.
The current price level is 0.76%, 12.53%, and -9.32% away from its SMA20, SMA50, and SMA200 respectively, with the ATOS price moving below the 50-day SMA on February 17. Atossa Therapeutics Inc. (ATOS) stock is up 10.51% over the week and -3.96% over the past month. Its price is 51.81% year-to-date and -41.86% over the past year.
The company’s next earnings report is expected on 05/11/2023, with forecasts estimating quarterly EPS at $0 and -$0.22 for whole year.
Its 12-month price target is $6.00. To reach the target analysts have set, the stock logically needs to grow 86.67 percent from here. Of course, the average price target is just what the average analysts believe a stock will be worth in the next 52 weeks, and is only one metric. There are analysts with lower targets than the average, including one bearish Wall Street research firm advocating investors to wait for the price to pull back to $6.00, given the recent momentum. And then, on the bullish side of things, one analyst is expecting the stock to peak at $6.00.
Outstanding shares total 126.62M with insiders holding 0.04% of the shares and institutional holders owning 21.74% of the company’s common stock. The company has a return on equity of -18.50%. The beta has a value of 1.24. Price to book ratio is 0.83.
Fidelity Extended Market Index Fu cut their holdings by -0.41% in the company over the course of the most recent quarter. It now holds a 0.53% position in Atossa Therapeutics Inc. thanks to 0.67 million shares amounting to $0.54 million.
